In medulloblastoma models, EA further targets and inhibits the Shh signaling-driven E2F1/PPARγ axis, reducing the expression of key glycolytic enzymes (e.g., HKII, PKM2) and impairing glucose uptake efficiency, ultimately suppressing tumor cell proliferation (66). Here, PPARG is linked to neoplasm.